Navigation Links
Regado Biosciences to Present at the Rodman & Renshaw Global Investment Conference on September 10, 2009
Date:9/3/2009

BASKING RIDGE, N.J., Sept. 3 /PRNewswire/ -- Regado Biosciences, a privately held company leading the development of antithrombotic aptamers with active control agents, announced today that David J. Mazzo, Ph.D., President and Chief Executive Officer, will be presenting at the 11th Annual Healthcare Conference of the Rodman & Renshaw Global Investment Conference in New York, NY at 4:30 PM on Thursday, September 10, 2009 (EDT). Dr. Mazzo's presentation will include an overview of the Company's pipeline with emphasis on the lead development program, the anticoagulant system, REG1.

ABOUT REGADO BIOSCIENCES

Regado Biosciences is pioneering a new therapeutic technology with the creation and development of two-component drug systems. Each system comprises a nuclease-stabilized RNA aptamer that can be controlled directly by its specific and complementary oligonucleotide active control agent. This technology is being applied to injectable antithrombotics, including anticoagulants and antiplatelet agents, a multi-billion dollar market in need of therapeutics with improved safety profiles and a greater degree of therapeutic control. Regado's technology is designed to give physicians the ability to actively and directly control each system's therapeutic effect providing a safe and unique approach to personalized medicine.

ABOUT REG1

Regado's lead program, the anticoagulant system REG1, consists of two parenteral agents, the first being a potent highly selective Factor IXa inhibitor (RB006) and the second being its complementary active control agent (RB007). RB007 can be used to selectively completely or partially reverse the anticoagulant effect of RB006.

ABOUT APTAMERS

RB006 is a member of a class of compounds called aptamers. Aptamers are single stranded oligonucleotides that adopt a specific conformation enabling direct, specific inhibition of the targeted protein. A key unique feature of aptamers derives from the fact that they are formed from nucleic acids. As such, their pharmacologic activity can be controlled by a matched, complementary oligonucleotide active control agent (the Watson-Crick base pair complement of a fraction of the agent to be controlled), which can bind to the aptamer, removing it from its target and reversing it biologic effects.

More information can be found at http://www.regadobio.com.


'/>"/>
SOURCE Regado Biosciences
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Regado Biosciences REG1 Anticoagulation System Study Results Published in the Journal of Thrombosis and Haemostasis
2. David J. Mazzo, Ph.D., Joins Regado Biosciences as President and CEO
3. Regado Biosciences to Present at the Piper Jaffray Health Care Conference on Tuesday, December 2, 2008
4. Ellen McDonald Joins Regado Biosciences as Senior Vice President of Business Operations and Chief Business Officer
5. Regado Biosciences To Present at the 27th Annual J.P. Morgan Healthcare Conference
6. Dr. Steven L. Zelenkofske Joins Regado Biosciences as Senior Vice President, Clinical and Medical Affairs and Chief Medical Officer
7. Regado Biosciences Establishes Medical Advisory Board
8. Regado Biosciences Expands Medical Advisory Board
9. Regado Biosciences Announces First Patient Enrolled In Phase 1 Study Of Subcutaneously Administered Reg1 Anticoagulation System
10. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
11. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2019)... Calif. (PRWEB) , ... October 30, 2019 , ... ... 29, 2019 to showcase the many roles innovation and technology play in educating ... Center for Innovation, featured hands-on learning opportunities and presentations by WesternU administrators and ...
(Date:10/22/2019)... ... October 22, 2019 , ... nQ Medical, Inc. of Cambridge, ... Most Fundable Companies List which was announced at a showcase event yesterday in Los ... annual revenue, strong business plans, and impressive near-term growth projections to be named one ...
(Date:10/17/2019)... ... October 16, 2019 , ... My Gene ... information, has published a new white paper that explores how frequently medical management ... to how patients and medical providers can be kept informed as changes are ...
(Date:10/10/2019)... ... October 10, 2019 , ... VirTrial today ... centers in Europe. All Pratia research centers have completed VirTrial’s Virtual Trial Capable ... certified as Virtual Trial Capable and prepared to conduct decentralized clinical trials (DCT). ...
Breaking Biology Technology:
(Date:11/14/2019)... , ... November 13, 2019 , ... ... Robert Peterson, RAC , a regulatory affairs and program management executive with ... and medical device industries, has joined the firm as an Expert Consultant. ...
(Date:11/14/2019)... , ... November 13, 2019 , ... Personalized Stem ... first patients in an FDA approved clinical trial for stem cell treatment of ... formation of the company as a subsidiary of VetStem Biopharma. , In July of ...
(Date:11/12/2019)... ... November 12, 2019 , ... ... orthopedic medical devices, today announced the creation of a Global Regulatory Affairs Department, ... Medical Device industry is that the regulatory element to any Medtech organization is ...
Breaking Biology News(10 mins):